Efforts to prevent another Martin Shkreli-like abuse of FDA incentives are proving difficult, in part because of the potential effects on the US agency.
The Biotechnology Innovation Organization warned a proposed tweak to the tropical disease priority review voucher program intended to ensure a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?